JAMP-ZOLEDRONIC ACID SOLUTION

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE)

Saadav alates:

JAMP PHARMA CORPORATION

ATC kood:

M05BA08

INN (Rahvusvaheline Nimetus):

ZOLEDRONIC ACID

Annus:

4MG

Ravimvorm:

SOLUTION

Koostis:

ZOLEDRONIC ACID (ZOLEDRONIC ACID MONOHYDRATE) 4MG

Manustamisviis:

INTRAVENOUS

Ühikuid pakis:

5 ML

Retsepti tüüp:

Prescription

Terapeutiline ala:

BONE RESORPTION INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0141761002; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2018-11-07

Toote omadused

PRODUCT MONOGRAPH
Pr
JAMP-ZOLEDRONIC ACID
(Zoledronic Acid for Injection)
4 mg Zoledronic acid/5 mL incorporated as the monohydrate
Sterile liquid concentrate must be diluted before use
Bone Metabolism Regulator
JAMP Pharma Corporation
Date of Preparation:
1310 Rue Nobel
November 7, 2018
Boucherville, Québec
J4B 5H3
Control # 220781
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE
REACTIONS..................................................................................................11
DRUG INTERACTIONS
..................................................................................................19
DOSAGE AND ADMINISTRATION
..............................................................................20
OVERDOSAGE
................................................................................................................23
ACTION AND CLINICAL PHARMACOLOGY
............................................................25
STORAGE AND STAB
IL
I
T
Y
..........................................................................................29
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................29
PART II: SCIENTIFIC
INFORMATION
...............................................................................30
PHARMACEUTICAL
INFORMATION..........................................................................30
CLINICAL
TR
IA
L
S
..........................................................................................................31
DETAILED PHARMACOLOGY
..